All In Biotech

Free tool

FAERS Monitor: Blujepa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218230 or its brand name (Blujepa, Gepotidacin Mesylate). Reports on generic versions are filed under their own applications.

Reports

33

Serious

2

6% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea8
  • drug ineffective5
  • off label use3
  • abdominal pain2
  • dizziness2
  • dysarthria2
  • nausea2
  • abdominal pain upper1
  • asthenia1
  • back pain1
  • drug intolerance1
  • dysuria1
  • faeces soft1
  • feeling abnormal1
  • hospitalisation1

Reports by year received

View as table
YearReports
20221
20251
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,126 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
faeces soft187.612.721
dysarthria233.98.835
dysuria117.32.53
diarrhoeaSignal87.94.343
drug intolerance16.61.01
abdominal pain25.51.44
hospitalisation14.10.60
abdominal pain upper13.10.40
back pain12.70.40
feeling abnormal12.70.40
dizziness22.60.71
drug ineffective52.41.13
off label use32.20.71
asthenia11.70.20
nausea21.60.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.